Good morning and happy Sunday!

It was a risk-on week across the board, as investors cheered a new US-UK trade pact and a potential thaw in China talks. The Nasdaq Composite roared back, and Bitcoin popped above $100K. President Donald Trump explicitly told investors to “buy” — and plenty took it to heart.

This week, we tracked a Republican senator quietly dipping into Alphabet stock, Morningstar doubling down on Nvidia, and CVS Health seeing a massive $154 million insider sell-off. These trades come amid broader investor optimism, but not everyone is leaning in the same direction.

Here’s how it all went down.

P.S. This newsletter was drafted Friday. Want these trade alerts as they happen? Join Elite Insider here.

🧘 Google Drama Didn’t Scare Off This Senator

U.S. Senator Shelley Moore Capito (R-WV) purchased a stake in Alphabet Inc. $GOOGL ( ▲ 1.3% ) , valued between $1,001 and $15,000, according to a filing released May 7.

The dollar amount might not be eye-popping, but the timing is. Alphabet is navigating substantial regulatory turmoil, with multiple courts calling the company a monopoly, and calls for a breakup mounting. Moreover, the stock declined significantly in the previous week after Apple’s $AAPL ( ▲ 0.54% ) services chief told a federal court he believes AI search tools will eventually replace traditional search engines like Google.

Capito, who sits on the Senate Appropriations Committee, may have insight into where federal tech policy is headed. So it seems telling that she’s aligning herself with one of the market’s AI powerhouses. Alphabet’s continued investment in Gemini and cloud infrastructure might just make it a prescient move.

💊 CVS Director Sheds $154M Worth of Stock

On May 2, 2025, Larry Robbins, CEO of Glenview Capital Management and CVS Health Corp. $CVS ( ▼ 0.42% ) Board Member, reported the sale of 2,276,068 shares at a price of $67.86, totaling a staggering $154.4 million.

That’s not small change — and while Robbins still holds nearly 10 million shares, this sale is hard to ignore. CVS has been under pressure lately, facing questions around its PBM business, tighter margins in retail pharmacy, and whether its aggressive push into healthcare services will deliver the expected payoff.

Robbins is a hedge fund veteran, and large sales like this often reflect portfolio rebalancing. But given the size of the transaction, it’s worth wondering if he’s locking in gains ahead of expected turbulence.

Want to learn how to leverage INSIDER TRADING ACTIVITY to potentially beat the market?

Look no further than ELITE INSIDER (EI) — a complete ‘all in one’ software dashboard and scanner that tracks the political, corporate, and hedge fund insider trading activity.

EI includes cluster buying, largest trade and most active trade scanners, interactive charting+data suite and our Insider Portfolio Alerts (IPA). It’s time to bridge the gap from main street to Wall Street by following smart money insiders.

See you on the ‘INSIDE.’

🧠 Morningstar Ups the Ante on Nvidia

Morningstar Investment Management LLC increased its position in Nvidia Corp. $NVDA ( ▲ 1.8% ), bringing its total holdings to 262,501 shares. The move was disclosed on May 7.

Nvidia’s rally has been supercharged by surging demand for AI infrastructure, and Morningstar clearly isn’t afraid of heights. The firm’s buy came at an average price of $108.38, reinforcing its belief in AI’s long-term trajectory.

Morningstar tends to play the fundamentals. It’s possible it is betting Nvidia’s data center dominance and expanding software ecosystem will offset any cyclical downturn in consumer GPUs. With the stock still riding the “Magnificent 7” wave, it’s a strong show of confidence from one of the industry's more disciplined allocators.